Teprotumumab for dysthyroid optic neuropathy: a systematic review and pooled analysis of 81 eyes evaluating outcomes, safety, and durability

To review the efficacy, safety, and durability of teprotumumab (TEP) in the treatment of dysthyroid optic neuropathy (DON). A PROSPERO-registered systematic review (CRD420261442289) was conducted in accordance with PRISMA 2020 guidelines. Five databases were searched through July 2026. Studies reporting 1 or more patients with DON managed with TEP were included. Fourteen studies comprising 52 patients (81 eyes) were included. The sample-weighted mean age was 66.5 years and 29 of 46 patients with documented sex (63.0%) were female. Prior corticosteroids had been administered in 50 patients (96.2%) and orbital decompression in 20 patients (38.5%), while only 2 patients (3.8%) were treatment-naïve. Visual acuity improved in 39 of 44 eyes (88.6%) with individual paired data. Colour vision improved in all 39 assessable eyes (100%). The weighted mean proptosis reduction was 4.2 mm across 77 eyes (range, 1–10 mm) and mean clinical activity score improvement was 4.98 points (23 patients). Rapid optic nerve response within two infusions occurred in 32 of 49 assessable patients (65.3%). Diplopia resolved in only 4 of 11 evaluable patients (36.4%). Across 42 evaluable patients, 3 experienced TED relapse and 3 patients developed DON recurrence. Adverse events included hearing loss, tinnitus or dysacusis (n = 6), hyperglycaemia (n = 4), muscle spasms and gastrointestinal distress (n = 4). Teprotumumab produces rapid recovery of optic nerve function, clinical activity, and proptosis as salvage therapy for DON. Recurrent DON and TED reactivation are, however, not uncommon with uncertain durability of response.

Authors

Publication Details

Journal
Figshare
Published
2026-11-18
DOI
https://doi.org/10.6084/m9.figshare.35045227
Primary Topic
Ophthalmology and Eye Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Teprotumumab for dysthyroid optic neuropathy: a systematic review and pooled analysis of 81 eyes evaluating outcomes, safety, and durability

Tarjani Vivek Dave, Dinesh Selva, Jai Paris, Ayushi Agarwal
4 links
Figshare
Ophthalmology and Eye Disorders
article

Teprotumumab for dysthyroid optic neuropathy: a systematic review and pooled analysis of 81 eyes evaluating outcomes, safety, and durability

Tarjani Vivek Dave, Dinesh Selva, Jai Paris, Ayushi Agarwal
article en

Abstract

To review the efficacy, safety, and durability of teprotumumab (TEP) in the treatment of dysthyroid optic neuropathy (DON). A PROSPERO-registered systematic review (CRD420261442289) was conducted in accordance with PRISMA 2020 guidelines. Five databases were searched through July 2026. Studies reporting 1 or more patients with DON managed with TEP were included. Fourteen studies comprising 52 patients (81 eyes) were included. The sample-weighted mean age was 66.5 years and 29 of 46 patients with documented sex (63.0%) were female. Prior corticosteroids had been administered in 50 patients (96.2%) and orbital decompression in 20 patients (38.5%), while only 2 patients (3.8%) were treatment-naïve. Visual acuity improved in 39 of 44 eyes (88.6%) with individual paired data. Colour vision improved in all 39 assessable eyes (100%). The weighted mean proptosis reduction was 4.2 mm across 77 eyes (range, 1–10 mm) and mean clinical activity score improvement was 4.98 points (23 patients). Rapid optic nerve response within two infusions occurred in 32 of 49 assessable patients (65.3%). Diplopia resolved in only 4 of 11 evaluable patients (36.4%). Across 42 evaluable patients, 3 experienced TED relapse and 3 patients developed DON recurrence. Adverse events included hearing loss, tinnitus or dysacusis (n = 6), hyperglycaemia (n = 4), muscle spasms and gastrointestinal distress (n = 4). Teprotumumab produces rapid recovery of optic nerve function, clinical activity, and proptosis as salvage therapy for DON. Recurrent DON and TED reactivation are, however, not uncommon with uncertain durability of response.

Figshare
Good health and well-being
Ophthalmology and Eye Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon